ReviewDialogues in clinical neuroscience2026
Treatment of posttraumatic stress disorder (PTSD).
Review in Dialogues in clinical neuroscience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The present review summarises recommendations for the management of posttraumatic stress disorder (PTSD) based on a consensus among international experts in the field. Cognitive-behavioural therapy (CBT) has the best evidence base as a psychotherapy modality. Virtual reality exposure therapy appears to be an emerging treatment option for PTSD. Eye Movement Desensitisation and Reprocessing (EMDR) therapy and digital CBT-based interventions did not demonstrate superiority compared to controls. Controlled studies supporting the use of psychodynamic therapy are lacking. Early prophylactic psychotherapy for trauma victims is ineffective and may be harmful. First-line pharmacotherapy includes selective serotonin reuptake inhibitors (SSRIs) and the serotonin-noradrenaline reuptake inhibitor (SNRI) venlafaxine. Several second- and third-line medications are available for treatment-refractory patients. Currently, no medications can be recommended for prophylactic use in trauma victims. Although evidence is incomplete regarding combined psychotherapy and pharmacotherapy, available studies generally favour combination treatments over monotherapy. Repetitive transcranial magnetic stimulation (rTMS) showed efficacy in one study. In children and adolescents with PTSD, CBT demonstrated a medium effect size compared to active controls, while studies on SSRI treatment in this population yielded inconsistent results.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.